What is Honore Tage’s remaining Vanda Pharmaceuticals (VNDA) share ownership after the sale?

After selling 30,000 shares, Honore Tage directly owns 93,469 shares of Vanda Pharmaceuticals common stock. This figure reflects his remaining stake reported in the filing immediately following the disclosed open-market transaction.

Director Honore Tage sells 30,000 Vanda (NASDAQ: VNDA) shares at $8.03

Q: Was the Vanda Pharmaceuticals (VNDA) insider transaction a buy or a sell?

The transaction was a sale of Vanda Pharmaceuticals common stock. Honore Tage executed an open-market sale, disposing of 30,000 shares at a reported price of $8.03 per share according to the Form 4 details.

Q: Does the Vanda Pharmaceuticals (VNDA) Form 4 show direct or indirect ownership for Honore Tage?

The Form 4 identifies Honore Tage’s holdings as direct ownership . After the open-market sale of 30,000 shares, his directly held position in Vanda Pharmaceuticals common stock stands at 93,469 shares, as reported in the filing.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vanda Pharmaceuticals director Honore Tage sold 30,000 shares of common stock in an open-market transaction at a price of $8.03 per share. After this sale, Tage directly owns 93,469 shares of Vanda Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 30,000 shares ($240,900)

Net Sell 1 txn

Insider Honore Tage

Role Director

Sold 30,000 shs ($241K)

Type	Security	Shares	Price	Value
Sale	Common Stock	30,000	$8.03	$241K

Holdings After Transaction: Common Stock — 93,469 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/24/2026 - 04:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Honore Tage

(Last)

(First)

(Middle)

C/O VANDA PHARMACEUTICALS INC.

2200 PENNSYLVANIA AVENUE, SUITE 300E

(Street)

WASHINGTON

20037

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [ VNDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/23/2026		S		30,000	D	$8.03	93,469	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Tage Honore	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Vanda Pharmaceuticals (VNDA) director Honore Tage report on this Form 4?

Honore Tage reported selling 30,000 shares of Vanda Pharmaceuticals common stock. The transaction was an open-market sale at $8.03 per share, and it changed Tage’s direct holdings to 93,469 shares following the sale.

How many Vanda Pharmaceuticals (VNDA) shares did Honore Tage sell and at what price?

Honore Tage sold 30,000 shares of Vanda Pharmaceuticals common stock at $8.03 per share. This open-market transaction reduced his direct ownership position while providing a clear record of the sale price and number of shares transacted.

Was the Vanda Pharmaceuticals (VNDA) insider transaction a buy or a sell?

The transaction was a sale of Vanda Pharmaceuticals common stock. Honore Tage executed an open-market sale, disposing of 30,000 shares at a reported price of $8.03 per share according to the Form 4 details.

What type of transaction did Vanda Pharmaceuticals (VNDA) report for Honore Tage?

The filing shows an open-market sale of common stock by director Honore Tage. Classified under transaction code “S,” it represents a standard sale transaction rather than an option exercise, gift, or other non-market-related equity movement.

Does the Vanda Pharmaceuticals (VNDA) Form 4 show direct or indirect ownership for Honore Tage?

The Form 4 identifies Honore Tage’s holdings as direct ownership. After the open-market sale of 30,000 shares, his directly held position in Vanda Pharmaceuticals common stock stands at 93,469 shares, as reported in the filing.